Targeting the endocannabinoid system as a potential anticancer approach

References

• Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, Rudland PS, Smith PH, Ke Y. 2003. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene. 22:2739–2749.
   PubMed Web of Science ®Google Scholar
• Adinolfi B, Romanini A, Vanni A, Martinotti E, Chicca A, Fogli S, Nieri P. 2013. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol. 718:154–159.
   PubMed Web of Science ®Google Scholar
• Akimov MG, Gretskaya NM, Zinchenko GN, Bezuglov VV. 2015. Cytotoxicity of endogenous lipids N-acyl dopamines and their possible metabolic derivatives for human cancer cell lines of different histological origin. Anticancer Res. 35:2657–2661.
   PubMed Web of Science ®Google Scholar
• Akimov MG, Ashba AM, Gretskaya NM, Bezuglov VV. 2017. N-Acyl dopamines induce apoptosis in PC12 cell line via the GPR55 receptor activation. Dokl Biochem Biophys. 474:155–158.
   PubMed Web of Science ®Google Scholar
• Al Fayi MS, Gou X, Forootan SS, Al-Jameel W, Bao Z, Rudland PR, Cornford PA, Hussain SA, Ke Y. 2016. The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. Oncotarget. 7:82783–82797.
   PubMedGoogle Scholar
• Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA, Ke Y. 2017. Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. Oncotarget. 8:31041–31056.
   PubMedGoogle Scholar
• Alexander JP, Cravatt BF. 2005. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol. 12:1179–1187.
   PubMed Web of Science ®Google Scholar
• Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C. 2011. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene. 30:245–252.
   PubMed Web of Science ®Google Scholar
• Anghileri E, Eoli M, Paterra R, Ferroli P, Pollo B, Cuccarini V, Maderna E, Tringali G, Saini M, Salsano E, et al. 2012. FABP4 is a candidate marker of cerebellar liponeurocytomas. J Neurooncol. 108:513–519.
   PubMed Web of Science ®Google Scholar
• Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS. 2008. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 1781:200–212.
   PubMed Web of Science ®Google Scholar
• Ashba AM, Akimov MG, Gretskaya NM, Bezuglov VV. 2016. N-Acyl dopamines induce cell death in PC12 cell line via induction of nitric oxide generation and oxidative stress. Dokl Biochem Biophys. 467:81–84.
   PubMed Web of Science ®Google Scholar
• Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, Platzer W, Bálint Z, Zamarbide M, Dopeso-Reyes IG, Ricobaraza A, et al. 2014. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br J Pharmacol. 171:5387–5406.
   PubMed Web of Science ®Google Scholar
• Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. 1995. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:143–147.
   PubMed Web of Science ®Google Scholar
• Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, Lucianò R, Canals D, Hannun Y, Hedlund P, Lavorgna G, et al. 2017. Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. Sci Rep. 7:42157
   PubMed Web of Science ®Google Scholar
• Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V. 2001. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15:2745–2747.
   PubMed Web of Science ®Google Scholar
• Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DI Marzo V. 2004. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18:1606–1608.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S, Di Marzo V. 1998. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells – implications for cell proliferation and differentiation. Eur J Biochem. 254:634–642.
   PubMedGoogle Scholar
• Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 134:845–852.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. 2000. N-Acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 351 Pt 3:817–824.
   PubMed Web of Science ®Google Scholar
• Björklund E, Blomqvist A, Hedlin J, Persson E, Fowler CJ. 2014. Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study. PLoS One. 9:e103479
   PubMed Web of Science ®Google Scholar
• Björklund E, Norén E, Nilsson J, Fowler CJ. 2010. Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br J Pharmacol. 161:1512–1526.
   PubMed Web of Science ®Google Scholar
• Blankman JL, Simon GM, Cravatt BF. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 14:1347–1356.
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P. 2005. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 517:174–181.
   PubMed Web of Science ®Google Scholar
• Brantl SA, Khandoga AL, Siess W. 2014. Mechanism of platelet activation induced by endocannabinoids in blood and plasma. Platelets. 25:151–161.
   PubMed Web of Science ®Google Scholar
• Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD. 2010. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis. 31:1584–1591.
   PubMed Web of Science ®Google Scholar
• Brown KJ, Laun AS, Song ZH. 2017. Cannabidiol, a novel inverse agonist for GPR12. Biochem Biophys Res Commun. 493:451–454.
   PubMed Web of Science ®Google Scholar
• Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. 2006. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66:6615–6621.
   PubMed Web of Science ®Google Scholar
• Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, et al. 2011. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 178:1953–1964.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen H, Li Y, Li L, Qiu Y, Ren J. 2015. Endocannabinoid and ceramide levels are altered in patients with colorectal cancer. Oncol Rep. 34:447–454.
   PubMed Web of Science ®Google Scholar
• Chen R, Feng C, Xu Y. 2011. Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res. 39:533–540.
   PubMed Web of Science ®Google Scholar
• Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, Mancini G, Lutz B, Bergh A, Fowler CJ. 2009. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer. 45:174–182.
   PubMed Web of Science ®Google Scholar
• Cipriano M, Gouveia-Figueira S, Persson E, Nording M, Fowler CJ. 2014. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes. 7:441.
   PubMedGoogle Scholar
• Cozzolino R, Calì G, Bifulco M, Laccetti P. 2010. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. Invest New Drugs. 28:115–123.
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:83–87.
   PubMed Web of Science ®Google Scholar
• Das R, Hammamieh R, Neill R, Melhem M, Jett M. 2001. Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res. 7:1706–1715.
   PubMed Web of Science ®Google Scholar
• Das SK, Paria BC, Chakraborty I, Dey SK. 1995. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA. 92:4332–4336.
   PubMed Web of Science ®Google Scholar
• Davies JW, Hainsworth AH, Guerin CJ, Lambert DG. 2010. Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. Br J Anaesth. 104:596–602.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V. 2002. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol. 16:297–302.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. 2011. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 163:1479–1494.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 95:8375–8380.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di Marzo V. 2012. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 204:255–266.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, Di Marzo V. 2008. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 325:1007–1015.
   PubMed Web of Science ®Google Scholar
• Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, Childers SR. 1993. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept Channels. 1:121–134.
   PubMedGoogle Scholar
• Desarnaud F, Cadas H, Piomelli D. 1995. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem. 270:6030–6035.
   PubMed Web of Science ®Google Scholar
• Deutsch DG. 2016. A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Front Pharmacol. 7:370.
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Chin SA. 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:791–796.
   PubMed Web of Science ®Google Scholar
• Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:605–613.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• Di Marzo V. 2009. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 60:77–84.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L. 1998. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J. 331 (Pt 1):15–19.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L. 2012. Why do cannabinoid receptors have more than one endogenous ligand?. Philos Trans R Soc Lond B: Biol Sci. 367:3216–3228.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. 2002. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids. 66:377–391.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:686–691.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L. 2001. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 358:249–255.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Piscitelli F. 2015. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 12:692–698.
   PubMed Web of Science ®Google Scholar
• Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD, Banerjee S, Oates JA, Marnett LJ. 2011. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol. 7:803–809.
   PubMed Web of Science ®Google Scholar
• Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V. 2004. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. Br J Pharmacol. 142:509–518.
   PubMed Web of Science ®Google Scholar
• Eichele K, Ramer R, Hinz B. 2009. R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway. Pharm Res. 26:346–355.
   PubMed Web of Science ®Google Scholar
• Eichele K, Weinzierl U, Ramer R, Brune K, Hinz B. 2006. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm Res. 23:90–94.
   PubMed Web of Science ®Google Scholar
• Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K. 2008. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 123:1318–1326.
   PubMed Web of Science ®Google Scholar
• EMA: Committee for Orphan Medicinal Products, Public Summary of Opinion on Orphan designation. 2015. Dronabinol and cannabidiol for the treatment of glioma. Orphan Drug Designation-Number: EU/3/15/1564; EMEA-Number: EMA/COMP/607076/2015. European Medicines Agency; [accessed 2017 Dec 18]. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/11/WC500196699.pdf
   Google Scholar
• Fang LY, Wong TY, Chiang WF, Chen YL. 2010. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med. 39:342–348.
   PubMed Web of Science ®Google Scholar
• Finlay DB, Joseph WR, Grimsey NL, Glass M. 2016. GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-arachidonoyl glycine. PeerJ. 4:e1835
   PubMed Web of Science ®Google Scholar
• FDA: Orphan Drug Designations and Approvals. Treatment of glioma. 2014. US Food and Drug Administration; [accessed 2017 Dec 18]. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey =450814
   Google Scholar
• FDA: Orphan Drug Designations and Approvals. Treatment of glioma. 2015. US Food and Drug Administration; [accessed 2017 Dec 18]. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey =498215
   Google Scholar
• Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. 2002. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:294–298.
   PubMed Web of Science ®Google Scholar
• Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Al Fayi MS, Al-Jameel W, Rudland PS, Hussain SA, et al. 2016. Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget. 7:9322–9339.
   PubMedGoogle Scholar
• Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, Rudland PS, Foster CS, Ke Y. 2014. The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol. 44:265–275.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. 2012. Anandamide uptake explained? Trends Pharmacol Sci. 33:181–185.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. 2014. Has FLAT fallen flat? Trends Pharmacol Sci. 35:51–52.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. 2015. Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clin Pharmacol Ther. 97:587–596.
   PubMed Web of Science ®Google Scholar
• Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, Lodola A, Armirotti A, Garau G, et al. 2011. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci. 15:64–69.
   PubMed Web of Science ®Google Scholar
• Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez D, Fonseca F, Rosengarth A, Luecke HD, Giacomo B, et al. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 425:90–93.
   PubMed Web of Science ®Google Scholar
• Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K, Hirohashi S. 2005. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics. 5:1411–1422.
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. 2000. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 6:313–319.
   PubMed Web of Science ®Google Scholar
• Gjerstorff MF, Benoit VM, Laenkholm AV, Nielsen O, Johansen LE, Ditzel HJ. 2006. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. Int J Oncol. 28:1327–1335.
   PubMed Web of Science ®Google Scholar
• Gómez del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M. 2002. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 363(Pt 1):183–188.
   Web of Science ®Google Scholar
• Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. 2000. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 57:1045–1050.
   PubMed Web of Science ®Google Scholar
• Goparaju SK, Ueda N, Taniguchi K, Yamamoto S. 1999. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol. 57:417–423.
   PubMed Web of Science ®Google Scholar
• Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H, Takata M, Aburatani H, Hoon DS, et al. 2006. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res. 66:4443–4449.
   PubMed Web of Science ®Google Scholar
• Gouveia-Figueira S, Karlsson J, Deplano A, Hashemian S, Svensson M, Fredriksson Sundbom M, Congiu C, Onnis V, Fowler CJ. 2015. Characterisation of (R)-2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor. PLoS One. 10:e0139212.
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G, et al. 2006. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res. 312:363–373.
   PubMed Web of Science ®Google Scholar
• Gromov P, Espinoza JA, Talman ML, Honma N, Kroman N, Timmermans Wielenga V, Moreira JM, Gromova I. 2014. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast. PLoS One. 9:e112024
   PubMed Web of Science ®Google Scholar
• Grupenmacher AT, Halpern AL, Bonaldo Mde F, Huang CC, Hamm CA, de Andrade A, Tomita T, Sredni ST. 2013. Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK). Childs Nerv Syst. 29:1977–1983.
   PubMed Web of Science ®Google Scholar
• Guaita-Esteruelas S, Bosquet A, Saavedra P, Gumà J, Girona J, Lam EW, Amillano K, Borràs J, Masana L. 2017. Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. Mol Carcinog. 56:208–217.
   PubMed Web of Science ®Google Scholar
• Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando P, Insabato L, et al. 2010. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology. 151:921–928.
   PubMed Web of Science ®Google Scholar
• Gustafsson K, Christensson B, Sander B, Flygare J. 2006. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212–2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol. 70(5):1612–20
   PubMed Web of Science ®Google Scholar
• Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. 2006. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 95:197–203.
   PubMed Web of Science ®Google Scholar
• Guzmán M, Sánchez C, Galve-Roperh I. 2001. Control of the cell survival/death decision by cannabinoids. J Mol Med (Med). 78:613–625.
   PubMed Web of Science ®Google Scholar
• GWP: GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma. 2017. Cambridge (UK): GW Pharmaceuticals; [accessed 2017 Dec 18]. https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-achieves-positive-results-phase-2-proof-concept-study-glioma
   Google Scholar
• Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM. 2011. Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One. 6:e26823.
   PubMed Web of Science ®Google Scholar
• Hamtiaux L, Masquelier J, Muccioli GG, Bouzin C, Feron O, Gallez B, Lambert DM. 2012. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer. 12:92.
   PubMed Web of Science ®Google Scholar
• Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2001. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA. 98:3662–3665.
   PubMed Web of Science ®Google Scholar
• Hanus L, Gopher A, Almog S, Mechoulam R. 1993. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 36:3032–3034.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl C, Feuersinger D, Sturm EM, Bärnthaler T, Heitzer E, Graf R, Grill M, Pichler M, Beck S, Butcher L, et al. 2018. G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer. 142:121–132.
   PubMed Web of Science ®Google Scholar
• Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B. 2014. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol. 92:312–325.
   PubMed Web of Science ®Google Scholar
• Held-Feindt J, Dörner L, Sahan G, Mehdorn HM, Mentlein R. 2006. Cannabinoid receptors in human astroglial tumors. J Neurochem. 98:886–893.
   PubMed Web of Science ®Google Scholar
• Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, Waldhoer M. 2011. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol. 25:1835–1848.
   PubMedGoogle Scholar
• Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 87:1932–1936.
   PubMed Web of Science ®Google Scholar
• Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, et al. 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 300:1295–1297.
   PubMed Web of Science ®Google Scholar
• Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. 2014. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci. 35:358–367.
   PubMed Web of Science ®Google Scholar
• Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, Colbran RJ, Reese J, Marnett LJ, Patel S. 2013. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci. 16:1291–1298.
   PubMed Web of Science ®Google Scholar
• Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, Podgorski I. 2013. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget. 4:2108–2123.
   PubMedGoogle Scholar
• Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. 2004a. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol. 66:1643–1651.
   PubMed Web of Science ®Google Scholar
• Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. 2004b. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun. 324:621–626.
   PubMed Web of Science ®Google Scholar
• Howlett AC. 1984. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1803–1810.
   PubMed Web of Science ®Google Scholar
• Howlett AC. 1985. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 27:429–436.
   PubMed Web of Science ®Google Scholar
• Howlett AC, Qualy JM, Khachatrian LL. 1986. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 29:307–313.
   PubMed Web of Science ®Google Scholar
• Huang H, McIntosh AL, Martin GG, Landrock D, Chung S, Landrock KK, Dangott LJ, Li S, Kier AB, Schroeder F. 2016. FABP1: a novel hepatic endocannabinoid and cannabinoid binding protein. Biochemistry. 55:5243–5255.
   PubMed Web of Science ®Google Scholar
• Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, et al. 2002. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA. 99:8400–8405.
   PubMed Web of Science ®Google Scholar
• Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, et al. 2014. Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther. 13:996–1007.
   PubMed Web of Science ®Google Scholar
• Iannotti FA, Di Marzo V, Petrosino S. 2016. Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res. 62:107–128.
   PubMed Web of Science ®Google Scholar
• Inoue M, Takahashi Y, Fujii T, Kitagawa M, Fukusato T. 2014. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma. World J Gastroenterol. 20:17541–17551.
   PubMed Web of Science ®Google Scholar
• Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B. 2003. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia. 17:1880–1890.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, et al. 2008. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Med). 86:89–98.
   PubMed Web of Science ®Google Scholar
• Jacobsson SO, Rongård E, Stridh M, Tiger G, Fowler CJ. 2000. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol. 60:1807–1813.
   PubMed Web of Science ®Google Scholar
• Jacobsson SO, Wallin T, Fowler CJ. 2001. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 299:951–959.
   PubMed Web of Science ®Google Scholar
• Jeong CY, Hah YS, Cho BI, Lee SM, Joo YT, Jung EJ, Jeong SH, Lee YJ, Choi SK, Ha WS, et al. 2012. Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma. Oncol Rep. 28:1283–1292.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Shen H, Tang B, Chen H, Yu Q, Ji X, Wang L. 2017. Identification of diagnostic markers involved in the pathogenesis of gastric cancer through iTRAQ-based quantitative proteomics. Data Brief. 11:122–126.
   PubMedGoogle Scholar
• Jin XH, Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. 2007. Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem. 282:3614–3623.
   PubMed Web of Science ®Google Scholar
• Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PH, Ke Y. 2001. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res. 61:4357–4364.
   PubMed Web of Science ®Google Scholar
• Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, et al. 2007. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 152:825–831.
   PubMed Web of Science ®Google Scholar
• Jung J, Hwang SW, Kwak J, Lee SY, Kang CJ, Kim WB, Kim D, Oh U. 1999. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J Neurosci. 19:529–538.
   PubMed Web of Science ®Google Scholar
• Jung CK, Kang WK, Park JM, Ahn HJ, Kim SW, Taek Oh S, Choi KY. 2013. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett. 5:870–876.
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Glaser ST, Deutsch DG. 2009. Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA. 106:6375–6380.
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Glaser ST, Maher T, Clavin B, Hamilton J, O'Rourke J, Rebecchi M, Puopolo M, Owada Y, Thanos PK. 2015. Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms. Mol Pain. 11:52.
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Rebecchi MJ, Ralph BP, Teng YH, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC, et al. 2014. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One. 9:e94200
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Vivieca S, Sun J, Glaser ST, Deutsch DG. 2012. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem. 287:3415–3424.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Marnett LJ. 1999. Discovery of a new class of selective cyclooxygenase-2 (COX-2) inhibitor that covalently modifies the isozyme. Adv Exp Med Biol. 469:139–143.
   PubMed Web of Science ®Google Scholar
• Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N. 2010. Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem. 285:19106–19115.
   PubMed Web of Science ®Google Scholar
• Kargl J, Andersen L, Hasenöhrl C, Feuersinger D, Stančić A, Fauland A, Magnes C, El-Heliebi A, Lax S, Uranitsch S, et al. 2016. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol. 173:142–154.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Kinameri A, Suzuki S, Senga S, Ke Y, Fujii H. 2016. The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis. Biochem J. 473:449–461.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee Y, Koo JS. 2015. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One. 10:e0119473.
   PubMed Web of Science ®Google Scholar
• King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, Qiu Y, Fu J, Mor M, Piomelli D. 2009. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol. 16:1045–1052.
   PubMed Web of Science ®Google Scholar
• Klein Nulent TJ, Van Diest PJ, van der Groep P, Leusink FK, Kruitwagen CL, Koole R, Van Cann EM. 2013. Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg. 51:604–609.
   PubMed Web of Science ®Google Scholar
• Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa M. 2006. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun. 347:827–832.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Rowlinson SW, Marnett LJ. 2000. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem. 275:33744–33749.
   PubMed Web of Science ®Google Scholar
• Ku CY, Liu YH, Lin HY, Lu SC, Lin JY. 2016. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget. 7:18229–18246.
   PubMedGoogle Scholar
• Laezza C, Pisanti S, Crescenzi E, Bifulco M. 2006. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 580:6076–6082.
   PubMed Web of Science ®Google Scholar
• Larrinaga G, Sanz B, Pérez I, Blanco L, Cándenas ML, Pinto FM, Gil J, López JI. 2010. Cannabinoid CB1 receptor is downregulated in clear cell renal cell carcinoma. J Histochem Cytochem. 58:1129–1134.
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. 2008. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA. 105:2699–2704.
   PubMed Web of Science ®Google Scholar
• Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T, Usami Y, Aikawa T, Okura M, Kamisaki Y, Kogo M. 2014. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep. 31:1116–1120.
   PubMed Web of Science ®Google Scholar
• Levi L, Lobo G, Doud MK, von Lintig J, Seachrist D, Tochtrop GP, Noy N. 2013. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res. 73:4770–4780.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, et al. 2003. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 125:677–687.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 318:1375–1387.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, et al. 2008. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 54:1–7.
   PubMed Web of Science ®Google Scholar
• Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. 2011. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol. 178:997–1008.
   PubMed Web of Science ®Google Scholar
• Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. 2005. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 67:15–19.
   PubMed Web of Science ®Google Scholar
• Lu VB, Puhl HL III, Ikeda SR. 2013. N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. Mol Pharmacol. 83:267–282.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Attinà M, Cartoni A, Bari M, Finazzi-Agrò A. 2001. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem. 76:594–601.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Dainese E, Oddi S. 2010. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci. 35:601–608.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Pauselli R, Di Rienzo M, Finazzi-Agrò A. 2002. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J. 366:137–144.
   PubMed Web of Science ®Google Scholar
• Mackie K, Devane WA, Hille B. 1993. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 44:498–503.
   PubMed Web of Science ®Google Scholar
• Markey SP, Dudding T, Wang TC. 2000. Base- and acid-catalyzed interconversions of O-acyl- and N-acyl-ethanolamines: a cautionary note for lipid analyses. J Lipid Res. 41:657–662.
   PubMed Web of Science ®Google Scholar
• Martin GG, Chung S, Landrock D, Landrock KK, Huang H, Dangott LJ, Peng X, Kaczocha M, Seeger DR, Murphy EJ, et al. 2016. FABP-1 gene ablation impacts brain endocannabinoid system in male mice. J Neurochem. 138:407–422.
   PubMed Web of Science ®Google Scholar
• Martin GG, Chung S, Landrock D, Landrock KK, Dangott LJ, Peng X, Kaczocha M, Murphy EJ, Kier AB, Schroeder F. 2016. Female mice are resistant to Fabp1 gene ablation-induced alterations in brain endocannabinoid levels. Lipids. 51:1007–1020.
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:561–564.
   PubMed Web of Science ®Google Scholar
• McHugh D, Page J, Dunn E, Bradshaw HB. 2012. Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 165:2414–2424.
   PubMed Web of Science ®Google Scholar
• McHugh D, Roskowski D, Xie S, Bradshaw HB. 2014. Δ(9)-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18. Front Pharmacol. 4:162.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:83–90.
   PubMed Web of Science ®Google Scholar
• Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. 2000. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 141:118–126.
   PubMed Web of Science ®Google Scholar
• Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M, Di Marzo V. 1999. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463:235–240.
   PubMed Web of Science ®Google Scholar
• Messalli EM, Grauso F, Luise R, Angelini A, Rossiello R. 2014. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol. 211:234.e1–236.
   PubMed Web of Science ®Google Scholar
• Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Müller MW, Giese NA, Friess H, et al. 2008. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 122:742–750.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart JP. 2003. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 56:1–12.
   PubMed Web of Science ®Google Scholar
• Mita R, Beaulieu MJ, Field C, Godbout R. 2010. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem. 285:37005–37015.
   PubMed Web of Science ®Google Scholar
• Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabissi M. 2014. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer. 134:2534–2546.
   PubMed Web of Science ®Google Scholar
• Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, et al. 2014. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem. 289:21960–21972.
   PubMed Web of Science ®Google Scholar
• Morihiro Y, Yasumoto Y, Vaidyan LK, Sadahiro H, Uchida T, Inamura A, Sharifi K, Ideguchi M, Nomura S, Tokuda N, et al. 2013. Fatty acid binding protein 7 as a marker of glioma stem cells. Pathol Int. 63:546–553.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay B, Schuebel K, Mukhopadhyay P, Cinar R, Godlewski G, Xiong K, Mackie K, Lizak M, Yuan Q, Goldman D, et al. 2015. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 61:1615–1626.
   PubMed Web of Science ®Google Scholar
• Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. 1975. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 55:597–602.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:61–65.
   PubMed Web of Science ®Google Scholar
• Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, Pallini R, Santoni G. 2015. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer. 137:1855–1869.
   PubMed Web of Science ®Google Scholar
• Nabissi M, Morelli MB, Santoni M, Santoni G. 2013. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 34:48–57.
   PubMed Web of Science ®Google Scholar
• Nakane S, Oka S, Arai S, Waku K, Ishima Y, Tokumura A, Sugiura T. 2002. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys. 402:51–58.
   PubMed Web of Science ®Google Scholar
• Nevo J, Mai A, Tuomi S, Pellinen T, Pentikäinen OT, Heikkilä P, Lundin J, Joensuu H, Bono P, Ivaska J. 2010. Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion. Oncogene. 29:6452–6463.
   PubMed Web of Science ®Google Scholar
• Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 17:1498–1503.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB. 2004. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 64:8826–8830.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB. 2011. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat. 94:34–43.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. 2010. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 140:49–61.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt BF. 2011. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 18:846–856.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SE, Kendall DA, Randall MD. 2006. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther. 317:428–438.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA. 2009. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol. 612:61–68.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. 2005. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun. 337:824–831.
   PubMed Web of Science ®Google Scholar
• Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, Kim JI, Kim S, Rhim H, O'Dell DK, et al. 2008. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem. 283:21054–21064.
   PubMed Web of Science ®Google Scholar
• Ohmachi T, Inoue H, Mimori K, Tanaka F, Sasaki A, Kanda T, Fujii H, Yanaga K, Mori M. 2006. Fatty acid binding protein 6 is overexpressed in colorectal cancer. Clin Cancer Res. 12:5090–5095.
   PubMed Web of Science ®Google Scholar
• Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T. 2003. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem. 85:1374–1381.
   PubMed Web of Science ®Google Scholar
• Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I. 2009. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2. Br J Cancer. 101:940–950.
   PubMed Web of Science ®Google Scholar
• Orellana-Serradell O, Poblete CE, Sanchez C, Castellón EA, Gallegos I, Huidobro C, Llanos MN, Contreras HR. 2015. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep. 33:1599–1608.
   PubMed Web of Science ®Google Scholar
• Ortega A, García-Hernández VM, Ruiz-García E, Meneses-García A, Herrera-Gómez A, Aguilar-Ponce JL, Montes-Servín E, Prospero-García O, Del Angel SA. 2016. Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells. Life Sci. 165:56–62.
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, et al. 2006. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3:167–175.
   PubMed Web of Science ®Google Scholar
• Pagano E, Borrelli F, Orlando P, Romano B, Monti M, Morbidelli L, Aviello G, Imperatore R, Capasso R, Piscitelli F, et al. 2017. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. Pharmacol Res. 119:227–236.
   PubMed Web of Science ®Google Scholar
• Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grübler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, et al. 2001. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 86:2687–2696.
   PubMed Web of Science ®Google Scholar
• Pan X, Ikeda SR, Lewis DL. 1996. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol. 49:707–714.
   PubMed Web of Science ®Google Scholar
• Park SW, Hah JH, Oh SM, Jeong WJ, Sung MW. 2016. 5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-l-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells. BMC Cancer. 16:458.
   PubMed Web of Science ®Google Scholar
• Park SW, Kim JE, Oh SM, Cha WJ, Hah JH, Sung MW. 2015. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species. Head Neck. 37:1187–1192.
   PubMed Web of Science ®Google Scholar
• Patsos HA, Greenhough A, Hicks DJ, Al Kharusi M, Collard TJ, Lane JD, Paraskeva C, Williams AC. 2010. The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J Oncol. 37:187–193.
   PubMed Web of Science ®Google Scholar
• Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, et al. 2015. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst. 107:djv077.
   PubMedGoogle Scholar
• Pérez-Gómez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, Guzmán M, Sánchez C. 2013. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene. 32:2534–2542.
   PubMed Web of Science ®Google Scholar
• Petersen G, Moesgaard B, Schmid PC, Schmid HH, Broholm H, Kosteljanetz M, Hansen HS. 2005. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem. 93:299–309.
   PubMed Web of Science ®Google Scholar
• Petrosino S, Di Marzo V. 2010. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs. 11:51–62.
   PubMed Web of Science ®Google Scholar
• Piñeiro R, Maffucci T, Falasca M. 2011. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene. 30:142–152.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M. 2007. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 211:495–503.
   PubMed Web of Science ®Google Scholar
• Portella G, Laezza C, Laccetti P, D, Petrocellis L, D, Marzo V, Bifulco M. 2003. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17:1771–1773.
   PubMed Web of Science ®Google Scholar
• Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, et al. 2002. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 301:1020–1024.
   PubMed Web of Science ®Google Scholar
• Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, Shilo K, Ganju RK. 2015. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget. 6:6373–6385.
   PubMedGoogle Scholar
• Prescott SM, Majerus PW. 1983. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem. 258:764–769.
   PubMed Web of Science ®Google Scholar
• Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M. 2012. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol. 227:250–258.
   PubMed Web of Science ®Google Scholar
• Prusakiewicz JJ, Duggan KC, Rouzer CA, Marnett LJ. 2009. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry. 48:7353–7355.
   PubMed Web of Science ®Google Scholar
• Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM. 2008. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 28:6231–6238.
   PubMed Web of Science ®Google Scholar
• Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B. 2013. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 12:69–82.
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. 2008. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst. 100:59–69.
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. 2016. Antitumorigenic targets of cannabinoids – current status and implications. Expert Opin Ther Targets. 20:1219–1235.
   PubMed Web of Science ®Google Scholar
• Rao E, Singh P, Zhai X, Li Y, Zhu G, Zhang Y, Hao J, Chi YI, Brown RE, Cleary MP, et al. 2015. Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein. Oncotarget. 6:7815–7827.
   PubMedGoogle Scholar
• Redmond WJ, Cawston EE, Grimsey NL, Stuart J, Edington AR, Glass M, Connor M. 2016. Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. Br J Pharmacol. 173:115–127.
   PubMed Web of Science ®Google Scholar
• Ross RA. 2003. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 140:790–801.
   PubMed Web of Science ®Google Scholar
• Ross RA. 2011. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci. 32:265–269.
   PubMed Web of Science ®Google Scholar
• Rovito D, Giordano C, Vizza D, Plastina P, Barone I, Casaburi I, Lanzino M, De Amicis F, Sisci D, Mauro L, et al. 2013. Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF-7 breast cancer cells. J Cell Physiol. 228:1314–1322.
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 152:1092–1101.
   PubMed Web of Science ®Google Scholar
• Saghatelian A, Trauger SA, Want EJ, Hawkins EG, Siuzdak G, Cravatt BF. 2004. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry. 43:14332–14339.
   PubMed Web of Science ®Google Scholar
• Sailler S, Schmitz K, Jäger E, Ferreiros N, Wicker S, Zschiebsch K, Pickert G, Geisslinger G, Walter C, Tegeder I, et al. 2014. Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. Oncoscience. 1:272–282.
   PubMedGoogle Scholar
• Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. 2001. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61:5784–5789.
   PubMed Web of Science ®Google Scholar
• Sanson B, Wang T, Sun J, Wang L, Kaczocha M, Ojima I, Deutsch D, Li H. 2014. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. Acta Crystallogr D Biol Crystallogr. 70:290–298.
   PubMedGoogle Scholar
• Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I. 2000. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472:39–44.
   PubMed Web of Science ®Google Scholar
• Sarnelli G, Gigli S, Capoccia E, Iuvone T, Cirillo C, Seguella L, Nobile N, D'Alessandro A, Pesce M, Steardo L, et al. 2016. Palmitoylethanolamide exerts antiproliferative effect and downregulates VEGF signaling in Caco-2 human colon carcinoma cell line through a selective PPAR-α-dependent inhibition of Akt/mTOR pathway. Phytother Res. 30:963–970.
   PubMed Web of Science ®Google Scholar
• Savinainen JR, Järvinen T, Laine K, Laitinen JT. 2001. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol. 134:664–672.
   PubMed Web of Science ®Google Scholar
• Schmid HH. 2000. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids. 108:71–87.
   PubMed Web of Science ®Google Scholar
• Schmid PC, Wold LE, Krebsbach RJ, Berdyshev EV, Schmid HH. 2002. Anandamide and other N-acylethanolamines in human tumors. Lipids. 37:907–912.
   PubMed Web of Science ®Google Scholar
• Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. 1997. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem. 40:659–667.
   PubMed Web of Science ®Google Scholar
• Simon GM, Cravatt BF. 2006. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 281:26465–26472.
   PubMed Web of Science ®Google Scholar
• Simon GM, Cravatt BF. 2008. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem. 283:9341–9349.
   PubMed Web of Science ®Google Scholar
• Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM. 1995. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol. 48:352–361.
   PubMed Web of Science ®Google Scholar
• Song GX, Shen YH, Liu YQ, Sun W, Miao LP, Zhou LJ, Liu HL, Yang R, Kong XQ, Cao KJ, et al. 2012. Overexpression of FABP3 promotes apoptosis through inducing mitochondrial impairment in embryonic cancer cells. J Cell Biochem. 113:3701–3708.
   PubMed Web of Science ®Google Scholar
• Steffens M, Schulze-Bonhage A, Surges R, Feuerstein TJ. 2005. Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci Lett. 385:13–17.
   PubMed Web of Science ®Google Scholar
• Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:773–778.
   PubMed Web of Science ®Google Scholar
• Stewart BW, Wild CP, editors, 2014. World cancer report 2014 Lyon: International Agency for Research on Cancer. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, et al. 1999. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure–activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem. 274:2794–2801.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K. 2000. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 275:605–612.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 215:89–97.
   PubMed Web of Science ®Google Scholar
• Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunk P, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R, et al. 2007. Potent and selective biphenylazole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett. 17:3511–3515.
   PubMed Web of Science ®Google Scholar
• Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ. 2007. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 152:734–743.
   PubMed Web of Science ®Google Scholar
• Sun YX, Tsuboi K, Okamoto Y, Tonai T, Murakami M, Kudo I, Ueda N. 2004. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J. 380(Pt 3):749–756.
   Web of Science ®Google Scholar
• Tang Z, Shen Q, Xie H, Zhou X, Li J, Feng J, Liu H, Wang W, Zhang S, Ni S. 2016. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget. 7:46253–46262.
   PubMedGoogle Scholar
• Takeda S, Ikeda E, Su S, Harada M, Okazaki H, Yoshioka Y, Nishimura H, Ishii H, Kakizoe K, Taniguchi A, et al. 2014. Δ(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARα in MDA-MB-231 breast cancer cells. Toxicology. 326:18–24.
   PubMed Web of Science ®Google Scholar
• Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limón P, Ren X, Lam TT, Schwartz GJ, de Araujo IE. 2013. A gut lipid messenger links excess dietary fat to dopamine deficiency. Science. 341:800–802.
   PubMed Web of Science ®Google Scholar
• Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L, Granfors T, Fowler CJ. 2010. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One. 5:e12275.
   PubMed Web of Science ®Google Scholar
• Thumser AE, Moore JB, Plant NJ. 2014. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care. 17:124–129.
   PubMed Web of Science ®Google Scholar
• Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G. 2009. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer. 9:248.
   PubMed Web of Science ®Google Scholar
• Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, et al. 2014. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 20:3280–3288.
   PubMed Web of Science ®Google Scholar
• Tyukhtenko S, Chan K, Jiang R, Zhou H, Mercier RW, Yang DP, Makriyannis A, Guo JJ. 2015. Hydrogen-bonded His93 as a sensitive probe for identifying inhibitors of the endocannabinoid transport protein FABP7. Chem Biol Drug Des. 85:534–540.
   PubMed Web of Science ®Google Scholar
• Uehara H, Takahashi T, Oha M, Ogawa H, Izumi K. 2014. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer. 135:2558–2568.
   PubMed Web of Science ®Google Scholar
• Vara D, Morell C, Rodríguez-Henche N, Diaz-Laviada I. 2013. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis. 4:e618.
   PubMed Web of Science ®Google Scholar
• Wang B, Tao X, Huang CZ, Liu JF, Ye YB, Huang AM. 2014. Decreased expression of liver-type fatty acid-binding protein is associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology. 61:1321–1326.
   PubMedGoogle Scholar
• Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. 2008. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 68:6468–6476.
   PubMed Web of Science ®Google Scholar
• Wang J, Ueda N. 2009. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 89:112–119.
   PubMed Web of Science ®Google Scholar
• Wang W, Chu HJ, Liang YC, Huang JM, Shang CL, Tan H, Liu D, Zhao YH, Liu TY, Yao SZ. 2016. FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer. Tumour Biol. 37:14873–14883.
   PubMedGoogle Scholar
• Wang YT, Liu CH, Zhu HL. 2016. Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015). Expert Opin Ther Pat. 26:767–776.
   PubMed Web of Science ®Google Scholar
• White AC, Munson JA, Munson AE, Carchman RA. 1976. Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst. 56:655–658.
   PubMedGoogle Scholar
• Winkler K, Ramer R, Dithmer S, Ivanov I, Merkord J, Hinz B. 2016. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget. 7:15047–15064.
   PubMedGoogle Scholar
• Woodward DF, Wang JW, Poloso NJ. 2013. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics. Pharmacol Rev. 65:1135–1147.
   PubMed Web of Science ®Google Scholar
• Wu M, Huang J, Zhang J, Benes C, Jiao B, Ren R. 2017. N-Arachidonoyl dopamine inhibits NRAS neoplastic transformation by suppressing its plasma membrane translocation. Mol Cancer Ther. 16:57–67.
   PubMed Web of Science ®Google Scholar
• Wu X, Han L, Zhang X, Li L, Jiang C, Qiu Y, Huang R, Xie B, Lin Z, Ren J, et al. 2012. Alteration of endocannabinoid system in human gliomas. J Neurochem. 120:842–849.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, et al. 2006. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 171:31–38.
   PubMed Web of Science ®Google Scholar
• Yan F, Shen N, Pang JX, Zhang YW, Rao EY, Bode AM, Al-Kali A, Zhang DE, Litzow MR, Li B, et al. 2017. Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells. Leukemia. 31:1434–1442.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang B, Seviour EG, Tao KX, Liu XH, Ling Y, Chen JY, Wang GB. 2011. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 307:6–17.
   PubMed Web of Science ®Google Scholar
• Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA. 2009. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem. 284:12328–12338.
   PubMed Web of Science ®Google Scholar
• Yousef BA, Hassan HM, Zhang LY, Jiang ZZ. 2017. Anticancer potential and molecular targets of pristimerin: a mini-review. Curr Cancer Drug Targets. 17:100–108.
   PubMed Web of Science ®Google Scholar
• Yu M, Ives D, Ramesha CS. 1997. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 272:21181–21186.
   PubMed Web of Science ®Google Scholar
• Zhang J, Medina-Cleghorn D, Bernal-Mizrachi L, Bracci PM, Hubbard A, Conde L, Riby J, Nomura DK, Skibola CF. 2016. The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience. 3:31–41.
   PubMedGoogle Scholar
• Zhang W, Levi L, Banerjee P, Jain M, Noy N. 2015. Kruppel-like factor 2 suppresses mammary carcinoma growth by regulating retinoic acid signaling. Oncotarget. 6:35830–35842.
   PubMedGoogle Scholar
• Zhou J, Deng Z, Chen Y, Gao Y, Wu D, Zhu G, Li L, Song W, Wang X, Wu K, et al. 2015. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma. Urol Oncol. 33:113.e9–117.
   PubMed Web of Science ®Google Scholar
• Zibara K, Awada Z, Dib L, El-Saghir J, Al-Ghadban S, Ibrik A, El-Zein N, El-Sabban M. 2015. Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo. Sci Rep. 5:12598.
   PubMed Web of Science ®Google Scholar
• Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:452–457.
   PubMed Web of Science ®Google Scholar